We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
Read MoreHide Full Article
Key Takeaways
The VOR stock surged after licensing ex-China rights to telitacicept from RemeGen.
The licensing deal totals $125M upfront and stock, plus more than $4B in potential milestones and royalties.
VOR appoints Jean-Paul Kress as its new chief executive officer and chairman of the board.
Shares of Vor Bio (VOR - Free Report) have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based pharmaceutical company, to develop and commercialize the latter’s pipeline candidate, telitacicept, in ex-China markets.
Telitacicept, a novel dual-target fusion protein, is currently approved for treating certain autoimmune diseases, including generalized myasthenia gravis (gMG), systemic lupus erythematosus and rheumatoid arthritis in China.
Telitacicept uniquely blocks two key proteins, BAFF and APRIL, instead of one, which may help control autoimmune diseases better than currently available treatments. VOR will develop and commercialize telitacicept across the world, excluding China, Hong Kong, Macau and Taiwan.
A global phase III study evaluating telitacicept in gMG is currently underway in the United States, Europe and South America. The study is being conducted by RemeGen and initial data from the same is expected in the first half of 2027.
Concurrently, Vor Bio also announced the appointment of Jean-Paul Kress as its new chief executive officer and chairman with immediate effect. The company’s previous chief executive officer, Robert Ang’s resigned from his post at the same time.
Image Source: Zacks Investment Research
More on VOR's Licensing Deal With RemeGen
Per the latest agreement, Vor Bio has agreed to pay RemeGen $125 million, including $45 million upfront and $80 million in stock warrants at a minimal exercise price.
The deal also includes potential milestone payments of more than $4 billion, along with tiered royalties on future product sales to be paid by Vor Bio to RemeGen.
The licensing deal with RemeGen is likely to transform VOR into an emerging company with a focus on developing novel treatments for autoimmune diseases.
The deal has most likely saved Vor Bio from a complete shutdown of the business, which it announced last month. In May 2025, the company announced that it was winding down clinical and manufacturing operations and laid off around 95% of employees to explore strategic alternatives to maximize shareholder value, including a potential sale.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 31.2%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 185.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 9.2%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
Key Takeaways
Shares of Vor Bio (VOR - Free Report) have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based pharmaceutical company, to develop and commercialize the latter’s pipeline candidate, telitacicept, in ex-China markets.
Telitacicept, a novel dual-target fusion protein, is currently approved for treating certain autoimmune diseases, including generalized myasthenia gravis (gMG), systemic lupus erythematosus and rheumatoid arthritis in China.
Telitacicept uniquely blocks two key proteins, BAFF and APRIL, instead of one, which may help control autoimmune diseases better than currently available treatments. VOR will develop and commercialize telitacicept across the world, excluding China, Hong Kong, Macau and Taiwan.
A global phase III study evaluating telitacicept in gMG is currently underway in the United States, Europe and South America. The study is being conducted by RemeGen and initial data from the same is expected in the first half of 2027.
Concurrently, Vor Bio also announced the appointment of Jean-Paul Kress as its new chief executive officer and chairman with immediate effect. The company’s previous chief executive officer, Robert Ang’s resigned from his post at the same time.
Image Source: Zacks Investment Research
More on VOR's Licensing Deal With RemeGen
Per the latest agreement, Vor Bio has agreed to pay RemeGen $125 million, including $45 million upfront and $80 million in stock warrants at a minimal exercise price.
The deal also includes potential milestone payments of more than $4 billion, along with tiered royalties on future product sales to be paid by Vor Bio to RemeGen.
The licensing deal with RemeGen is likely to transform VOR into an emerging company with a focus on developing novel treatments for autoimmune diseases.
The deal has most likely saved Vor Bio from a complete shutdown of the business, which it announced last month. In May 2025, the company announced that it was winding down clinical and manufacturing operations and laid off around 95% of employees to explore strategic alternatives to maximize shareholder value, including a potential sale.
Vor Bio, Inc. Price
Vor Bio, Inc. price | Vor Bio, Inc. Quote
VOR's Zacks Rank & Stocks to Consider
Vor Bio currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) , Spero Therapeutics (SPRO - Free Report) and Puma Biotechnology (PBYI - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 31.2%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 185.5%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 9.2%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.